Which has better valuation & earnings, PCVX or BIIB?

Biogen has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxcyte N/A N/A -$766.63M -$7.63 N/A Biogen $9.89B 3.06 $1.29B $5.65 36.20

Is PCVX or BIIB more profitable?

Biogen has a net margin of 8.32% compared to Vaxcyte's net margin of 0.00%. Biogen's return on equity of 11.18% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -37.56% -33.62% Biogen 8.32% 11.18% 6.88%

Does the media prefer PCVX or BIIB?

In the previous week, Vaxcyte had 4 more articles in the media than Biogen. MarketBeat recorded 19 mentions for Vaxcyte and 15 mentions for Biogen. Vaxcyte's average media sentiment score of 0.80 beat Biogen's score of 0.77 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 9 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 5 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALNY or PCVX?

In the previous week, Vaxcyte had 1 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 19 mentions for Vaxcyte and 18 mentions for Alnylam Pharmaceuticals. Vaxcyte's average media sentiment score of 0.80 beat Alnylam Pharmaceuticals' score of 0.10 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Vaxcyte 9 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ROIV or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Roivant Sciences -3,534.96% -22.94% -21.53% Vaxcyte N/A -37.56% -33.62%

Does the media favor ROIV or PCVX?

In the previous week, Vaxcyte had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 19 mentions for Vaxcyte and 15 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.84 beat Vaxcyte's score of 0.80 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 5 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 9 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, INCY or PCVX?

Incyte has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.82B 4.20 $1.29B $7.85 15.35 Vaxcyte N/A N/A -$766.63M -$7.63 N/A

Is INCY or PCVX more profitable?

Incyte has a net margin of 27.71% compared to Vaxcyte's net margin of 0.00%. Incyte's return on equity of 29.93% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Incyte 27.71% 29.93% 22.88% Vaxcyte N/A -37.56% -33.62%

Does the media favor INCY or PCVX?

In the previous week, Vaxcyte had 13 more articles in the media than Incyte. MarketBeat recorded 19 mentions for Vaxcyte and 6 mentions for Incyte. Incyte's average media sentiment score of 1.05 beat Vaxcyte's score of 0.80 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 9 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BNTX or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -63.54% -6.86% -6.00% Vaxcyte N/A -37.56% -33.62%

Does the media favor BNTX or PCVX?

In the previous week, Vaxcyte had 6 more articles in the media than BioNTech. MarketBeat recorded 19 mentions for Vaxcyte and 13 mentions for BioNTech. Vaxcyte's average media sentiment score of 0.80 beat BioNTech's score of 0.41 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Vaxcyte 9 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vaxcyte (PCVX) Competitors

$60.04 +0.82 (+1.38%)

As of 10:49 AM Eastern

Compare

PCVX vs. BIIB, ALNY, ROIV, INCY, and BNTX

Should you buy Vaxcyte stock or one of its competitors? Vaxcyte's main competitors and comparable companies include Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Roivant Sciences (ROIV), Incyte (INCY), and BioNTech (BNTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Vaxcyte compare to Biogen?

Vaxcyte (NASDAQ:PCVX) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Biogen has a net margin of 8.32% compared to Vaxcyte's net margin of 0.00%. Biogen's return on equity of 11.18% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-37.56%	-33.62%
Biogen	8.32%	11.18%	6.88%

Biogen has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A
Biogen	$9.89B	3.06	$1.29B	$5.65	36.20

Vaxcyte has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market. Comparatively, Biogen has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market.

In the previous week, Vaxcyte had 4 more articles in the media than Biogen. MarketBeat recorded 19 mentions for Vaxcyte and 15 mentions for Biogen. Vaxcyte's average media sentiment score of 0.80 beat Biogen's score of 0.77 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	9 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	5 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte presently has a consensus target price of $86.00, indicating a potential upside of 43.25%. Biogen has a consensus target price of $224.61, indicating a potential upside of 9.80%. Given Vaxcyte's higher possible upside, equities analysts plainly believe Vaxcyte is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Biogen beats Vaxcyte on 10 of the 16 factors compared between the two stocks.

How does Vaxcyte compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Vaxcyte (NASDAQ:PCVX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

Alnylam Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Vaxcyte's net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Vaxcyte	N/A	-37.56%	-33.62%

Alnylam Pharmaceuticals has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	8.01	$313.75M	$5.38	41.32
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

In the previous week, Vaxcyte had 1 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 19 mentions for Vaxcyte and 18 mentions for Alnylam Pharmaceuticals. Vaxcyte's average media sentiment score of 0.80 beat Alnylam Pharmaceuticals' score of 0.10 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxcyte	9 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals presently has a consensus target price of $396.72, indicating a potential upside of 78.46%. Vaxcyte has a consensus target price of $86.00, indicating a potential upside of 43.25%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Alnylam Pharmaceuticals is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.92
Vaxcyte	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 3.3% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Alnylam Pharmaceuticals beats Vaxcyte on 11 of the 16 factors compared between the two stocks.

How does Vaxcyte compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Vaxcyte (NASDAQ:PCVX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Roivant Sciences has higher revenue and earnings than Vaxcyte. Roivant Sciences is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,160.26	-$299.77M	-$0.53	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

Vaxcyte has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Vaxcyte	N/A	-37.56%	-33.62%

In the previous week, Vaxcyte had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 19 mentions for Vaxcyte and 15 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.84 beat Vaxcyte's score of 0.80 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	5 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	9 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by insiders. Comparatively, 3.3% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Roivant Sciences has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market.

Roivant Sciences currently has a consensus price target of $35.14, indicating a potential downside of 3.18%. Vaxcyte has a consensus price target of $86.00, indicating a potential upside of 43.25%. Given Vaxcyte's higher possible upside, analysts clearly believe Vaxcyte is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Vaxcyte	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

Roivant Sciences beats Vaxcyte on 10 of the 16 factors compared between the two stocks.

How does Vaxcyte compare to Incyte?

Incyte (NASDAQ:INCY) and Vaxcyte (NASDAQ:PCVX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

Incyte has a net margin of 27.71% compared to Vaxcyte's net margin of 0.00%. Incyte's return on equity of 29.93% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Vaxcyte	N/A	-37.56%	-33.62%

In the previous week, Vaxcyte had 13 more articles in the media than Incyte. MarketBeat recorded 19 mentions for Vaxcyte and 6 mentions for Incyte. Incyte's average media sentiment score of 1.05 beat Vaxcyte's score of 0.80 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	9 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Incyte has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.82B	4.20	$1.29B	$7.85	15.35
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

Incyte has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market.

97.0% of Incyte shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 16.2% of Incyte shares are held by company insiders. Comparatively, 3.3% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Incyte currently has a consensus price target of $120.40, indicating a potential downside of 0.11%. Vaxcyte has a consensus price target of $86.00, indicating a potential upside of 43.25%. Given Vaxcyte's higher possible upside, analysts plainly believe Vaxcyte is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43
Vaxcyte	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

Incyte beats Vaxcyte on 12 of the 15 factors compared between the two stocks.

How does Vaxcyte compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Vaxcyte (NASDAQ:PCVX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

Vaxcyte has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Vaxcyte	N/A	-37.56%	-33.62%

In the previous week, Vaxcyte had 6 more articles in the media than BioNTech. MarketBeat recorded 19 mentions for Vaxcyte and 13 mentions for BioNTech. Vaxcyte's average media sentiment score of 0.80 beat BioNTech's score of 0.41 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxcyte	9 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech presently has a consensus target price of $127.81, suggesting a potential upside of 38.00%. Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 43.25%. Given Vaxcyte's higher possible upside, analysts clearly believe Vaxcyte is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Vaxcyte	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

Vaxcyte has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.65B	8.84	-$1.29B	-$7.83	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

15.5% of BioNTech shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 3.3% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

BioNTech has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market.

Summary

BioNTech and Vaxcyte tied by winning 8 of the 16 factors compared between the two stocks.

Get Vaxcyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PCVX vs. The Competition

Export

Metric	Vaxcyte	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.67B	$3.73B	$7.00B	$12.93B
Dividend Yield	N/A	3.76%	2.58%	10.34%
P/E Ratio	-7.87	10.39	268.52	25.24
Price / Sales	N/A	1,234.06	574.06	74.43
Price / Cash	N/A	102.54	72.26	50.42
Price / Book	3.24	18.24	13.31	6.21
Net Income	-$766.63M	-$13.23M	$3.44B	$347.05M
7 Day Performance	7.36%	3.71%	1.99%	1.43%
1 Month Performance	3.14%	-0.73%	-0.37%	-0.53%
1 Year Performance	100.12%	60.69%	70.61%	20.94%

Vaxcyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PCVX Vaxcyte	2.1797 of 5 stars	$60.04 +1.4%	$86.00 +43.2%	+99.6%	$8.67B	N/A	N/A	160	Earnings Report
BIIB Biogen	4.0649 of 5 stars	$201.82 -0.6%	$223.89 +10.9%	+59.3%	$29.99B	$9.89B	35.72	7,500
ALNY Alnylam Pharmaceuticals	4.8014 of 5 stars	$220.33 +7.2%	$402.67 +82.8%	-49.1%	$27.50B	$3.71B	40.95	2,770
ROIV Roivant Sciences	1.7183 of 5 stars	$33.32 -1.7%	$33.59 +0.8%	+215.6%	$24.39B	$8.26M	N/A	860	Analyst Forecast
INCY Incyte	3.4097 of 5 stars	$118.43 -0.9%	$119.60 +1.0%	+52.9%	$24.23B	$5.14B	15.09	2,844	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PCVX) was last updated on 8/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vaxcyte (PCVX) Competitors